Monograph Details
|
|
Ob/Gyn
> Menopause and HRT
|
|
MENEST |
| Manufacturer |
|
King Pharmaceuticals, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Estrogen. |
| Generic Name |
|
Esterified estrogens 0.3mg, 0.625mg, 1.25mg, 2.5mg; tabs. |
| Indications |
|
Moderate to severe vasomotor symptoms of menopause. Atrophic vaginitis. Kraurosis vulvae. Hypoestrogenism. |
| Children |
|
Not applicable. |
| Adults |
|
Menopause: 1.25mg daily, give cyclically (3 weeks on, 1week off); if menstruating use Day 5 start. Atrophic vaginitis, kraurosis vulvae: 0.3–1.25mg or more daily, give cyclically (3 weeks on, 1 week off). Hypogonadism: 2.5–7.5mg daily in divided doses for 20 days then stop for 10 days; repeat course if withdrawal bleeding does not occur within these 10 days. If bleeding occurs within 10 days, begin 20-day cyclic regimen adding an oral progestin. If bleeding occurs before this regimen is finished, discontinue therapy and may resume on Day 5 of bleeding. Female castration, primary ovarian failure: 1.25mg daily, cyclically. Reevaluate periodically. |
| Contraindications |
|
Thrombophlebitis. Thromboembolic disorders. Cerebrovascular or coronary artery disease. Pregnancy (Cat.X). |
| Precautions |
|
Hepatic dysfunction. Gallbladder disease. Conditions aggravated by fluid retention. Familial hyperlipoproteinemia. Discontinue if jaundice occurs. Nursing mothers. |
| Adverse Reactions |
|
See literature. Breakthrough bleeding, dysmenorrhea, mastodynia, migraine, depression, edema, weight changes, hypertension, GI upset. |
| How Supplied |
Tabs 2.5mg—50
0.3mg, 0.625mg, 1.25mg—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
